摘要
目的探讨硼替佐米联合地塞米松治疗老年多发性骨髓瘤的临床效果及对血小板生成素和免疫细胞水平的影响。方法选取2015年1月—2020年10月江西省上饶市立医院收治的40例老年多发性骨髓瘤患者作为研究对象,按照随机抽签法分为对照组(20例)和观察组(20例)。对照组采用长春新碱、地塞米松联合表柔比星治疗,观察组采用硼替佐米联合地塞米松治疗。比较两组的治疗效果,治疗前后免疫抑制因子[白介素-6(IL-6)和白介素-17(IL-17)]、免疫细胞(CD3^(+)CD4^(+)、CD3^(+)CD8^(+)和CD3^(+)CD4^(+)/CD3^(+)CD8^(+))、血小板生成素(TPO)、转化生长因子-β(TGF-β)水平的变化。结果治疗后,观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05);观察组IL-6、IL-17低于对照组,差异有统计学意义(P<0.05);观察组CD3^(+)CD4^(+)、CD3^(+)CD4^(+)/CD3^(+)CD8^(+)高于对照组,CD3^(+)CD8^(+)低于对照组,差异有统计学意义(P<0.05);观察组患者的TPO、TGF-β低于对照组,差异有统计学意义(P<0.05)。结论硼替佐米联合地塞米松治疗老年多发性骨髓瘤的临床效果显著,不仅能够改善患者的免疫抑制因子水平,还能够改善患者的免疫细胞水平,适合在临床进行实施和开展。
Objective To explore the clinical effect of Bortezomib combined with Dexamethasone in the treatment of elderly multiple myeloma and the influence on the levels of thrombopoietin and immune cells.Methods A total of 40 elderly patients with multiple myeloma admitted to Shangrao Municipal Hospital of Jiangxi Province from January 2015 to October 2020 were selected as the research objects and divided into the control group(20 cases)and the observation group(20 cases)according to the random drawing lots method.The control group was treated with Vincristine,Dexamethasone combined with Epirubicin,and the observation group was treated with Bortezomib combined with Dexamethasone.The therapeutic effects the levels of immunosuppressive factors(interleukin-6[IL-6]and interleukin-17[IL-17]),immune cells(CD3^(+)CD4^(+),CD3^(+)CD8^(+),CD3^(+)CD4^(+)/CD3^(+)CD8^(+)),thrombopoietin(TPO)and transforming growth factor-β(TGF-β)before and after treatment were compared between the two groups.Results After treatment,the total effective rate of the observation group was higher than that of the control group,the difference was statistically significant(P<0.05).The IL-6 and IL-17 of the observation group were lower than those of the control group,the differences were statistically significant(P<0.05).The CD3^(+)CD4^(+),CD3^(+)CD4^(+)/CD3^(+)CD8^(+)of the observation group were higher than those of the control group,the CD3^(+)CD8^(+)of the observation group was lower than that of the control group,the differences were statistically significant(P<0.05).The TPO and TGF-βin the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).Conclusion The clinical effect of Bortezomib combined with Dexamethasone in the treatment of elderly multiple myeloma is significant,which can not only improve the level of immunosuppressive factors,but also improve the level of immune cells,which is suitable for clinical implementation and development.
作者
芮明忠
王子妍
芦茜
RUI Ming-zhong;WANG Zi-yan;LU Xi(Department of Hematology,Shangrao Municipal Hospital,Jiangxi Province,Shangrao334000,China;Department of Hematology,Suzhou Hongci Hematology Hospital,Jiangsu Province,Suzhou215000,China)
出处
《中国当代医药》
CAS
2021年第22期55-58,共4页
China Modern Medicine
基金
江西省上饶市科技计划项目(20201CKJ25)。
